What could $5,000 invested in CSL shares become in 1 year?

Let's see what sort of returns analysts are tipping for this ASX giant.

| More on:
A young man goes over his finances and investment portfolio at home.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Over the last decade and a half, CSL Ltd (ASX: CSL) shares have been a great place to park your money.

During this time, the biotechnology giant's shares have generated a total average annual return of 16.4% per annum.

This means that if you had invested $5,000 into CSL's shares all the way back in 2009 and held tightly to them until today, your investment would have grown to be worth a mouth-watering ~$49,000.

This has been driven by the company's consistently strong performance underpinned by its in-demand plasma therapies, acquisitions, and its annual investment in research and development (R&D).

In respect to the latter, CSL reinvests in the region of 12% of its sales back into R&D activities each year. This has led to the development of some lucrative and life-saving therapies and vaccines, as well as a pipeline of future products to drive its growth.

But those gains have been and gone. What could happen if I invested $5,000 into the company's shares today? Would they be a good place to put my hard-earned money? Let's find out what analysts are saying about the biotechnology giant.

Should I invest $5,000 into CSL shares?

The majority of analysts in Australia are positive on CSL and see plenty of value in its shares at current levels.

For example, Morgans has an add rating and $315.40 price target on them. It recently described CSL as a key holding and named it on its best ideas list. The broker commented:

While shares have struggled of late, we continue to view CSL as a key portfolio holding and sector pick, offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares trading at 25x, a substantial discount (20%) to its long-term average.

Big returns are possible

Analysts at UBS and Macquarie see even more value in the company's shares at current levels. They both recently put the equivalent of buy ratings and $330.00 price targets on them.

At present, CSL shares are changing hands for $280.33. This means that for an investment of $5,045.94, I could pick up 18 units.

If those shares were to rise in value to UBS and Macquarie's price targets, they would have a market value of $5,940. That's approximately $900 more than my original investment.

But it gets better. Macquarie is so positive on the outlook for the key CSL Behring business that it believes the CSL share price could climb beyond $500 within three years. If this proves accurate, those 18 shares would have a market value of $9,000 in 2027.

All in all, it seems that the company's shares could be worth holding tightly to for some time to come.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Telix Pharmaceuticals share price sinks on unexpected Nasdaq news

ASX 200 investors are bidding down the Telix Pharmaceuticals share price today. But why?

Read more »

Health workers shake hands and congratulate each other on good news.
Healthcare Shares

This ASX 200 healthcare stock is up 48% in a year, but one director is still buying!

A director of this ASX 200 healthcare company has just lifted his personal stake by 50%.

Read more »

A man and woman in an office look at a laptop and discuss investing, budget strategies or other financial concepts
Healthcare Shares

Why this broker just upgraded Telix shares to a buy rating

Bell Potter thinks a recent pullback has created a buying opportunity.

Read more »

A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
Healthcare Shares

Sigma share price dives 6% on Chemist Warehouse merger hurdle

The proposed merger faces ACCC concerns.

Read more »

A person wrapped in warm clothing with head, eyes and face covered by a hat, glasses and a scarf is coated in a layer of snow and ice. representing Strike Energy's trading halt today
Healthcare Shares

Why is the Telix Pharmaceuticals share price frozen today?

Telix Pharmaceuticals shares won’t be moving today.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

3 ASX 300 healthcare stocks 'well positioned to outperform'

Wilsons thinks the healthcare sector could be about to outperform the broader market.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

CSL shares can 'absolutely' head to $500: ASX expert

This expert reckons it's foolish to bet against CSL...

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

2 ASX biotech shares that could be the next Telix Pharmaceuticals

These ASX biotech shares could become the next Telix Pharmaceuticals. But how?

Read more »